Duexis (Ibuprofen/FAmotidine) Patent Expiration, LOE Window & CMS Spending
Duexis (Ibuprofen/FAmotidine) by Amgen: FDA Orange Book LOE 2026-07-18, 4 AB generics, $600K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N022519 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-07-18 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $600K |
| 2024 Medicare Part D Spend | $368K |
| 2024 Medicaid Spend | $232K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.